RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Since I am not aware of any plan to develop a unique formulation or dosage form that would make it possible to differentiate and thus premium-price their version, the cost of the generic sets a ceiling on their pricing of a branded form for sleep apnea. How they will budget for marketing of the 'first drug for sleep apnea' out of that constrained revenue stream is an interesting question. On the other hand, the drug does not have to make a lot of money to be worthwhile to Cortex--it's a low fiscal bar to surpass.

NeuroPerspective